Read by QxMD icon Read

Muscle invasive bladder cancer

Akash A Kapadia, Ann Martinez Acevedo, Jen-Jane Liu, Mark Garzotto, Michael Conlin, Christopher Amling, Ryan P Kopp
PURPOSE: Neoadjuvant chemotherapy is an important adjunct to cystectomy in management of muscle invasive bladder cancer. We investigated factors that predict failure to receive surgery following multi-agent chemotherapy for non-metastatic muscle invasive bladder cancer utilizing the National Cancer Database. MATERIALS AND METHODS: We performed a cohort study including patients diagnosed with cT2-4aN0M0 urothelial cell carcinoma of the bladder between 2004 and 2013 who underwent multi-agent chemotherapy...
March 15, 2018: Journal of Urology
Xiaojing Huang, Hongwen Zhu, Zemin Gao, Junzun Li, Junlong Zhuang, Yu Dong, Bing Shen, Meiqian Li, Hu Zhou, Hongqian Guo, Ruimin Huang, Jun Yan
Once urinary bladder cancer (UBC) develops into muscle-invasive bladder cancer, its mortality rate increases dramatically. However, the molecular mechanisms of UBC invasion and metastasis remain largely unknown. Herein, using 5637 UBC cells, we generated two sublines with low (5637 NMI) and high (5637 HMI) invasive capabilities. Mass spectrum analyses revealed that the Wnt family protein Wnt7a is more highly expressed in 5637 HMI cells than in 5637 NMI cells. We also found that increased Wnt7a expression is associated with UBC metastasis and predicted worse clinical outcome in UBC patients...
March 16, 2018: Journal of Biological Chemistry
Masaki Momota, Shingo Hatakeyama, Noriko Tokui, Tendo Sato, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Satoshi Narita, Toshiaki Kawaguchi, Chikara Ohyama
BACKGROUND: The impact of preoperative renal impairment severity on prognosis in urothelial carcinoma remains unelucidated. OBJECTIVE: To evaluate the impact of severe preoperative renal insufficiency on oncological outcomes in patients with urothelial carcinoma who underwent radical cystectomy or nephroureterectomy. DESIGN, SETTING, AND PARTICIPANTS: A total of 1066 patients with urothelial carcinoma who underwent radical cystectomy or nephroureterectomy at six medical centres from February 1995 to November 2017 were retrospectively examined...
March 13, 2018: European Urology Focus
Chanjuan Wang, Aiwei Li, Shuo Yang, Rui Qiao, Xi Zhu, Jie Zhang
The emergence of chemoresistance greatly increases the recurrence risk for non-muscle invasive bladder cancer (NMIBC) patients, which is still a big concern of clinicians. Understanding the mechanisms of drug resistance is of great significance for preventing and reversing it. We showed here that CXC motif chemokine ligand 5 (CXCL5) was overexpressed in mitomycin C-resistant bladder cancer cell line M-RT4. Meanwhile, parental RT4 cell treated with recombinant human CXCL5 (rhCXCL5) reduced its sensitivity to mitomycin C...
March 12, 2018: Biochemical and Biophysical Research Communications
Suk Young Lee, Sang Hee Choi
Intravesical BCG therapy after transurethral resection of bladder tumor (TURB) is considered the most effective treatment for prophylaxis against the recurrence of high risk non-muscle invasive bladder cancer, and generally well tolerated and infectious complication are rare. We reported a case of granulomatous prostatitis is a patient who had undergone intravesical BCG therapy due to non-invasive superficial urothelial carcinoma of bladder. This patient was diagnosed by prostate biopsy because of PSA elevation without any other voiding symptoms and abnormal abscess pocket in transrectal ultrasonography...
March 2018: Urology Case Reports
Lara Kujtan, Arif Hussain, Janakiraman Subramanian, Ashiq Masood
PURPOSE OF REVIEW: Recent advances in next-generation sequencing have allowed for detailed molecular analysis of urothelial carcinomas, with potentially significant clinical implications for personalized treatment. Our objective in this review is to highlight studies from the past year that have furthered the understanding of urothelial cancer genomics. RECENT FINDINGS: Recent studies by The Cancer Genome Atlas consortium further characterized urothelial carcinomas via molecular subtyping, and a schema was proposed to match each subtype with potential therapeutic implications...
March 13, 2018: Current Opinion in Oncology
Syah Mirsya Warli, Dhirajaya Dharma Kadar, Ginanda Putra Siregar
BACKGROUND: Bladder cancer is the 9th most frequent cancer worldwide. Ki-67 is immunohistochemistry marker that is predictive of cancer cell proliferation. The expression of Ki-67 is associated with poor prognosis in several types of malignancy, yet the value of Ki-67 as the prognostic factor in bladder cancer remains controversial. AIM: This study is aimed to investigate the association between Ki-67 expression with muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC)...
February 15, 2018: Open Access Macedonian Journal of Medical Sciences
Naoya Niwa, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya
PURPOSE: It is still unknown whether switching the bacillus Calmette-Guérin (BCG) strain at the second induction course of BCG therapy has a therapeutic benefit in patients with tumor recurrence after the initial BCG therapy (BCG-relapsing tumor). MATERIALS AND METHODS: We retrospectively reviewed the clinicopathological features of 97 patients treated with a second induction course of BCG therapy between 1986 and 2014. Among the patients initially treated with BCG Tokyo-172, the second course was either BCG Tokyo-172 in 56 (57...
March 9, 2018: Urologic Oncology
Huakang Tu, Colin P Dinney, Yuanqing Ye, H Barton Grossman, Seth P Lerner, Xifeng Wu
Background: Patients with cancer are highly concerned about food choices and dietary supplements that may affect their treatment outcomes. Excess folic acid (synthetic folate) from supplements or fortification can lead to accumulation of unmetabolized folic acid in the systemic circulation and urine and may promote cancer growth, especially among those with neoplastic alterations. Objective: We investigated the prospective association between synthetic compared with natural folate intake and clinical outcomes in non-muscle-invasive bladder cancer (NMIBC), which is a highly recurrent disease...
February 1, 2018: American Journal of Clinical Nutrition
Willem Oosterlinck, Karel Decaestecker
Non-muscle-invasive bladder cancer (NMIBC) is a highly recurrent disease. Early bladder chemotherapy instillation (EBCI) after transurethral resection (TURB) is an efficient way to diminish recurrence. However, this method is often challenged. Areas covered: There was a recent publication of a large meta-analysis with the original patient data and the largest study ever on EBCI. Both brought new evidence on EBCI. Also the results of the 2 trials of EBCI with apaziquone appeared. EBCI is discussed among other methods to decrease recurrence...
March 15, 2018: Expert Review of Anticancer Therapy
Raffaella Santi, Tommaso Cai, Stefania Nobili, Ilaria Camilla Galli, Andrea Amorosi, Eva Comperat, Gabriella Nesi
The current WHO/ISUP classification and grading system subdivides urothelial tumours into prognostically distinct categories. Understanding the molecular pathways involved in bladder cancer development can improve patient stratification and management. This study aims to investigate the relationship between Snail, Slug and E-cadherin expressions and clinico-pathological features of non-muscle invasive bladder carcinoma (NMIBC). All patients attending the same urological centre from January to May 2002, who were pathologically diagnosed with NMIBC, were enrolled in this longitudinal cohort study...
March 10, 2018: Virchows Archiv: An International Journal of Pathology
Johannes Breyer, Ralph M Wirtz, Philipp Erben, Thomas S Worst, Robert Stoehr, Markus Eckstein, Simone Bertz, Danijel Sikic, Stefan Denzinger, Maximilian Burger, Arndt Hartmann, Wolfgang Otto
BACKGROUND: A recent study on the comprehensive genomic profile of advanced urothelial bladder cancer (UBC) showed cyclin-dependent kinase inhibitor 2A (CDKN2A) and fibroblast growth factor receptor 3 (FGFR3) as the most often clinically relevant genomic alterations. Therefore, the prognostic role of FGFR3 and CDKN2A/p16 for pT1 UBC was studied. PATIENTS AND METHODS: Clinical data and formalin-fixed paraffin-embedded tissues of pT1 UBC treated with an organ-preserving approach was analyzed retrospectively...
February 2, 2018: Clinical Genitourinary Cancer
Joshua S Jue, Tulay Koru-Sengul, Kevin J Moore, Feng Miao, Mahmoud Alameddine, Bruno Nahar, Sanoj Punnen, Dipen J Parekh, Chad R Ritch, Mark L Gonzalgo
INTRODUCTION: To investigate the impact of perioperative factors on overall survival among patients with histologic variants of bladder cancer treated with radical cystectomy. MATERIALS AND METHODS: The National Cancer Data Base was utilized to identify patients diagnosed with muscle-invasive bladder cancer (cT2-4, N0, M0) from 2004-2013. Variant histology bladder cancers (non-mucinous adenocarcinoma, mucinous/signet ring adenocarcinoma, micropapillary urothelial carcinoma, small cell carcinoma, and squamous cell carcinoma) were compared to urothelial carcinoma with respect to overall survival...
February 2018: Canadian Journal of Urology
Quentin Manach, Olivier Cussenot, Morgan Rouprêt, Xavier Gamé, Emmanuel Chartier-Kastler, Christine Reus, Philippe Camparo, Eva Compérat, Véronique Phé
INTRODUCTION: To establish if the validated tumor biomarkers of luminal and basal bladder cancers in non neuro-urological patients are applicable to a neuro-urological population. MATERIALS AND METHODS: We retrieved bladder cancer samples from neuro-urological patients (n = 20) and non-neurological controls (n = 40). The expression of GATA3 and CK5/6 was analyzed using immunohistochemistry of microarray tissue sections. We also assessed the correlation between previous biomarker expression, gender, age, tumor stage (non-muscle-invasive bladder cancer (NMIBC)/muscle-invasive bladder cancer (MIBC)), squamous-cell differentiation and basal/luminal subtypes using Pearson's correlation coefficient (r)...
February 2018: Canadian Journal of Urology
Marcus George Kwesi Cumberbatch, Beat Foerster, James W F Catto, Ashish M Kamat, Wassim Kassouf, Ibrahim Jubber, Shahrokh F Shariat, Richard J Sylvester, Paolo Gontero
CONTEXT: Initial treatment for most bladder cancers (BCs) involves transurethral resection (TUR) or tumours. Often more cancer is found after the initial treatment in around half of patients, requiring a second resection. Repeat transurethral resection (reTUR) is recommended for high-risk, non-muscle-invasive bladder cancer (NMIBC) to remove any residual disease and improve cancer outcomes. OBJECTIVE: To systematically review the practice and therapeutic benefit of an early reTUR for high-risk NMIBC...
March 6, 2018: European Urology
Islam M El-Babouly, Esam A E Desoky, Diab El Sayed, Maged M Ali, Ola A Harb, Ahmed Ragab, Ahmed M Sakr, Amr M Fawzi, Nashaat M Salama, Ibrahim I Samaha
OBJECTIVE: To report the sensitivity and specificity of neural precursor cell-expressed developmentally down-regulated protein 9 (NEDD9) protein high expression in predicting BCG response and its effect on recurrence or progression free survivals. PATIENTS AND METHODS: Between May 2014 and April 2017, a prospective cohort study was conducted on 105 patients with intermediate or high-risk nonmuscle invasive bladder cancer. Immunohistochemical staining with mouse monoclonal anti-NEDD9 antibody was done...
March 5, 2018: Urologic Oncology
Satoshi Inoue, Hiroki Ide, Kazutoshi Fujita, Taichi Mizushima, Guiyang Jiang, Takashi Kawahara, Seiji Yamaguchi, Hiroaki Fushimi, Norio Nonomura, Hiroshi Miyamoto
Using preclinical models, we have recently found that ELK1, a transcriptional factor that activates downstream targets, including c-fos proto-oncogene, induces bladder cancer outgrowth. Here, we immunohistochemically determined the expression status of phospho-ELK1, an activated form of ELK1, in upper urinary tract urothelial carcinoma (UUTUC). Overall, phospho-ELK1 was positive in 47 (47.5%; 37 weak (1+) and 10 moderate (2+)) of 99 UUTUCs, which was significantly ( P = 0.002) higher than in benign urothelium (21 (25...
March 8, 2018: International Journal of Molecular Sciences
Lutao Du, Weili Duan, Xiumei Jiang, Li Zhao, Juan Li, Rui Wang, Suzhen Yan, Yujiao Xie, Keqiang Yan, Qingliang Wang, Lili Wang, Yongmei Yang, Chuanxin Wang
Cell-free long non-coding RNAs (lncRNAs) are stably present in urine and can serve as non-invasive biomarkers for cancer. We aimed to identify signatures of lncRNAs in urine for diagnosis and prognosis of bladder cancer (BC). Screening of lncRNAs by microarray analysis was performed using urine samples of 10 BC patients and 10 controls. Expressions of candidate lncRNAs were evaluated in the training and validation set including 230 BC patients and 230 controls by quantitative reverse transcription polymerase chain reaction (qRT-PCR)...
March 8, 2018: Journal of Cellular and Molecular Medicine
Hangcheng Fu, Yu Zhu, Yiwei Wang, Zheng Liu, Junyu Zhang, Huyang Xie, Qiang Fu, Bo Dai, Dingwei Ye, Jiejie Xu
PURPOSE: This study aims to construct the stromal immunotype which could improve prediction of postsurgical survival and adjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS: A total of 118 MIBC patients from Shanghai Cancer Center, 140 MIBC patients from Zhongshan hospital and 287 MIBC patients from TCGA cohort were included in the study. Immune cell infiltration was evaluated by immunohistochemical staining or CIBERSORT method...
March 7, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Qiongli Su, Ting Tao, Lei Tang, Jun Deng, Kwame Oteng Darko, Sichun Zhou, Mei Peng, Shanping He, Qing Zeng, Alex F Chen, Xiaoping Yang
Pyruvate kinase M2 (PKM2) regulates the final step of glycolysis levels that are correlated with the sensitivity of anticancer chemotherapeutic drugs. THP is one of the major drugs used in non-muscle-invasive bladder cancer instillation chemotherapy. However, low response ratio of THP (19.7%) treatment to human genitourinary tumours using collagen gel matrix has been observed. This study aims to investigate the effect of down-regulation of PKM2 on THP efficiency. Via inhibitor or siRNA, the effects of reduced PKM2 on the efficiency of THP were determined in 2 human and 1 murine bladder cancer cell lines, using MTT, cologenic and fluorescence approaches...
March 7, 2018: Journal of Cellular and Molecular Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"